Fundraising Fox
Oxford Biodynamics
Oxford, GB · Incorporated in United Kingdom · 2 known investors
Find your way into Oxford Biodynamics
Sign up to see every warm intro you have to Oxford Biodynamics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oxford Biodynamics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oxford BioDynamics develops precision clinical diagnostic blood tests for detecting cancer and predicting treatment response in cancer patients, using its proprietary 3D genomic biomarker platform. The company serves oncologists and patients in the United States and internationally through its commercially available tests and partnerships with major pharmaceutical companies and research institutions.
Founders & leadership
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2021
▶$5MraisedNov 2021 · 1 investors · BiotechnologyRule 506(b)
- Alexandre AkoulitchevDirector
- David HolbrookDirector
- Stephen DiggleDirector
- Jon BurrowsExecutive Officer, Director
- Paul StockdaleExecutive Officer, Director
- Matthew WakefieldDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Oct 2021
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Companies House · registry record
View on Companies House ↗- Registered name
- OXFORD BIODYNAMICS PLC
- Company number
- 06227084
- Status
- Active
- Company type
- Public limited company
- Incorporated
- 25 Apr 2007
- Registered office
- 3140 Rowan Place John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB
- Nature of business (SIC)
- 21200 — Manufacture of pharmaceutical preparations
- Previous names
- OXFORD BIODYNAMICS LIMITED (2007–2016)
- Accounts
- last made up to 30 Sept 2025 · next due 31 Mar 2027
- Confirmation statement
- last made up to 25 Apr 2026 · next due 9 May 2027
Current officers · 8
- Alder Demain & Akers Limited — corporate secretary, appointed 3 Dec 2018
- Alexandre Akoulitchev — director, appointed 8 Jun 2007
- Richard Alan Compton — director, appointed 27 Aug 2026
- Martin Henry Diggle — director, appointed 15 Apr 2026
- David Mark Anthony Holbrook — director, appointed 5 Apr 2019
- Peter Eric Presland — director, appointed 17 Mar 2025
- Iain Gladstone Ross — director, appointed 31 Jan 2025
- Paul Leslie Stockdale — director, appointed 15 Sept 2017
Source: Companies House public register · retrieved 4 Oct 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Oxford Biodynamics do?
- Oxford BioDynamics develops precision clinical diagnostic blood tests for detecting cancer and predicting treatment response in cancer patients, using its proprietary 3D genomic biomarker platform. The company serves oncologists and patients in the United States and internationally through its commercially available tests and partnerships with major pharmaceutical companies and research institutions.
- Who founded Oxford Biodynamics?
- Oxford Biodynamics was founded by Alexandre Akoulitchev.
- Who are Oxford Biodynamics's investors?
- Oxford Biodynamics's investors include Seneca Partners, Vulpes Ventures.
- How much funding has Oxford Biodynamics raised?
- Oxford Biodynamics has disclosed $5M raised across 1 round.
- Where is Oxford Biodynamics headquartered?
- Oxford Biodynamics is headquartered in Oxford, GB.